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Abstract:  The  retrovirus  restriction  factor  TRIM5α  blocks  post-entry infection of 
retroviruses in a species-specific manner. As a cellular E3 ubiquitin ligase, TRIM5α binds 
to the retroviral capsid lattice in the cytoplasm of an infected cell and accelerates the 
uncoating process of retroviral capsid, thus providing a potent restriction to HIV-1 and 
other retrovirus infections. The precise mechanism by which this restriction is imposed 
remains under scrutiny, and evidence is lacking to link the E3 ubiquitin ligase activity of 
TRIM5α  to  its  ability  to  restrict  retrovirus  infection.  In  a  recent  study,  Pertel  and 
colleagues have uncovered the link between the two, providing compelling evidence to 
suggest that following the interaction with the retroviral capsid, TRIM5 triggers an 
antiviral innate immune response by functioning as a pattern recognition receptor [1]. This 
unique function of TRIM5 is dependent on its association with the E2 ubiquitin-
conjugating enzyme complex UBC13-UEV1A and subsequent activation of the TAK1 
kinase  complex  and  downstream  genes  involved  in  innate  immune  responses.  These 
findings  have defined a novel  function  for TRIM5 as a pattern recognition receptor in 
innate immune recognition and provided  valuable  mechanistic insight into its role as a 
retroviral restriction factor. Here we discuss the significance of these new findings in 
understanding TRIM5-mediated HIV restriction. 
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Given their limited genomic capacity, retroviruses such as HIV efficiently hijack the target cell’s 
machinery to complete their  lifecycle and generate virus progeny. Under the selective pressure of 
pathogenic infections,  the  host  has  evolved a variety of restriction factors to  block  retroviral 
replication,  and  consequently  retroviruses have evolved viral antagonists to overcome these  
restrictions  [2]. In the case  of HIV,  three  major  restriction factors  with distinct modes of action  
have been identified, including APOBEC3G  (apolipoprotein B mRNA-editing, enzyme-catalytic, 
polypeptide-like 3G) [3], tripartite motif-containing protein 5α (TRIM5α) [4], and tetherin (also known 
as BST-2 or CD317) [5,6]. However, HIV type 1 (HIV-1) possesses its own countermeasures in the 
likes of accessory proteins to engage and counteract these restriction factors. For instance, HIV-1 Vif 
protein counteracts APOBEC3G and HIV-1 Vpu protein counteracts tetherin. By contrast, no retroviral 
antagonist has been reported to overcome TRIM5α and the precise mechanism by which TRIM5α 
restricts HIV-1 replication in non-human primates remains to be defined (reviewed in [7,8]).  
In 2004, Stremlau and colleagues identified rhesus macaque TRIM5α as the factor responsible for 
blocking HIV-1 infection in Old World monkeys [4]. By contrast, human TRIM5α does not efficiently 
block HIV-1 infection [4], indicating the species-specific nature of the restrictive capacity of TRIM5α. 
This initial study showed the retrovirus  capsid  to  be  the  target  of  TRIM5α,  and  subsequent 
comparative studies with retroviruses from different genera have confirmed that TRIM5α-mediated 
restriction is dependent on its avidity for retroviral capsid [9]. Upon release into the target cell 
cytoplasm, the retroviral capsid is engaged by TRIM5α and forms an elaborate hexagonal lattice on top 
of the capsid and accelerates capsid uncoating, which blocks retrovirus infection [10-13]. However, 
cyclophilin A  (CypA),  another cytoplasmic protein  in human cells,  binds the HIV-1 capsid and 
protects HIV-1 from a putative CypA-regulated antiviral activity in human cells [14]. Interestingly, a 
previous study by the Luban laboratory uncovered a unique retrotransposition event in owl   
m on k ey ,  th e  on l y  N ew  W orl d  p ri m a te  th a t i s  re si s ta n t t o H I V -1, resulting in the expression of a 
TRIM5-Cyclophilin A (TRIMCyp) fusion protein that is potent in blocking HIV-1 infection [15]. The 
TRIMCyp fusion protein has now been successfully used in in vitro assays by Pertel and colleagues to 
delineate the restrictive mechanism of TRIM5α linking to innate immune signaling pathways [1].  
In an effort to understand the mechanism by which TRIM5α restricts retrovirus infection, Pertel and 
colleagues investigated the potential of TRIM5α as a signal transducer capable of activating NF-κB 
and AP-1-responsive genes involved in innate immune response [1], which can induce an antiviral 
state in the infected cell. This rationale was based on recent reports suggesting that TRIM5 plays a role 
in signal transduction processes [16,17]. Pertel et al. demonstrated that human TRIM5α, which does 
not efficiently restrict HIV-1 infection, is capable of activating mitogen  activated  protein  kinases 
(MAPK)- and NF-κB-dependent inflammatory genes, similar to those activated by the gram-negative 
bacterial  cell  wall  component,  lipopolysaccharide  (LPS).  Interestingly,  the authors showed that 
TRIM5α knockdown in myeloid cells attenuates the expression of LPS-induced inflammatory genes 
and also rescues the infection of HIV-1, SIV and non-retroviruses (vesicular stomatitis virus and 
Newcastle disease virus)  from  an  antiviral  state  established  by  LPS.  These  results  suggest  an 
involvement of TRIM5α in innate immune signaling, while the rescue of viral infection from LPS is 
independent  of  viral  capsid  recognition  by  TRIM5α.  Further  investigation  revealed  that  TRIM5α 
interacts with transforming growth factor beta-activated kinase 1 (TAK1), TAK1-binding protein 2 
(TAB2), and TAB3, components of the TAK1 kinase complex in order to activate MAPK and NF-κB Viruses 2011, 3                         
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signaling pathways.  This association is  also essential for the retrovirus capsid-specific restriction 
mediated by TRIM5α. The authors then asked the critical question whether TRIM5α’s E3 ubiquitin 
(Ub) ligase activity plays a role in its apparent innate immune signaling function.  
Ubiquitination is a post-translational modification of proteins that involves the covalent attachment 
of Ub to one or more lysine residues of a cellular protein via the concerted activity of three classes of 
enzyme termed E1 (Ub-activating enzymes), E2 (Ub-conjugating enzymes), and E3 (Ub-ligases). 
Traditionally, ubiquitination has been synonymous with tagging proteins for proteasomal degradation; 
however, an important role of ubiquitination in regulating immune responses is now being unraveled 
and appreciated (reviewed in [18]). In an attempt to uncover the link between TRIM5α’s E3 ligase 
activity and retrovirus  restriction,  Pertel  and  co-workers  revealed  that  TRIM5α  in  partnership  
with the heterodimeric E2 Ub-conjugating enzyme complex, UBC13-UEV1A (also known as UBE2N-
UBE2V1),  is capable of generating unattached, lysine 63 (K63)-linked  Ub  chains.  Upon 
multimerization, these free  polyubiquitin  chains  can  activate  the  TAK1  kinase  complex  by 
autophosphorylation  with the help of regulatory proteins, TAB2 and TAB3. These reactions were 
elegantly demonstrated in vitro by using the owl monkey TRIMCyp fusion protein to circumvent the 
technical challenges in purifying full-length recombinant TRIM5α protein. Moreover, human TRIM5α 
expressed and enriched from transfected human 293T cells also possesses the capacity to generate free 
K63 poly-Ub chains in vitro [1]. 
So how does TRIM5α trigger the formation of free K63-linked Ub chains and trigger an innate 
immune response during retrovirus infection? The authors suggest that TRIM5 does so by acting as a 
bona fide pattern recognition receptor that specifically senses retroviral capsid, which then triggers the 
E3 ligase  activity  of  TRIM5  to  activate  the  TAK1  kinase  complex,  resulting  in  the  activation  of  
innate  immune  signaling pathways. Furthermore, UBC13 and UEV1A, the components of the E2   
Ub-conjugating enzyme complex, interact with TRIM5 in addition to their previously known cellular 
partner TRAF6 (tumor necrosis factor receptor associated factor 6), which is an E3 Ub-ligase and 
plays an important role in NF-κB  regulatory  pathways  in  the  innate  immune  responses  against 
pathogens [18]. Therefore, the authors concluded that the E3 Ub-ligase activity and inflammatory gene 
induction function of TRIM5 are linked through its interactions with cellular factors including UBC13, 
UEV1A and TAK1, which also enhance capsid-specific restriction activity of TRIM5 (Figure 1). The 
authors  a l s o  s u g g e s t  t h a t  t h e  o r i g i n a l  f u n c t i o n  o f  T R I M 5  w a s  l i k e l y  t o  a c t  a s  a   pattern  
recognition receptor rather than a retrovirus restriction factor [1]. In contrast to these in vitro findings, 
Perez-Caballero and colleagues have previously shown that TRIM5-CypA-mediated restriction of 
HIV-1 is independent of the ubiquitination and proteasome function in owl monkey kidney cells [19]. 
It remains unclear to what extent TRIM5-induced innate immune responses rely upon ubiquitination to 
restrict HIV-1 or other retroviruses in human cells. Given that TRIM5α blocks retroviral infection in a 
species-specific manner, it is unclear whether the TRIM5  function as an innate immune sensor is 
dependent on the specific interaction  between  TRIM5  and  HIV-1  capsid protein.  It would be 
interesting to investigate whether TRIM5 interactions with other viral capsid proteins can also trigger 
the innate immune responses. 
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Figure 1. The  dual  role  of  TRIM5α  in  retrovirus infection.  The retrovirus capsid is 
engaged by TRIM5α in the cytoplasm of the infected cell and forms a hexagonal lattice on 
top of the capsid. This leads to aberrant uncoating of the capsid and  blocks retrovirus 
infection. Concomitantly, TRIM5α binding to capsid triggers its E3 ligase activity, and in 
concert with the E2 ubiquitin (Ub)-conjugating enzyme complex UBC13–UEV1A 
generates  free  lysine 63 (K63)-linked  Ub  chains, which  in turn are catalysts in the 
autophosphorylation (indicated as a  letter P i n  th e green  ci rcl e) of the TAK1 complex 
(includes  TAK1, TAB2, and TAB3). Activation of the TAK1 complex by 
autophosphorylation  results in  the induction and expression of NF-κB-  and  MAPK-
responsive inflammatory genes, thereby  leading to an innate immune response in the 
infected cell. 
 
 
Based on the study by Pertel et al., it is now clear that TRIM5α’s dual role in retrovirus infection 
serves not only to restrict the virus by attacking the retroviral capsid core, but also concomitantly 
triggers an ‘alarm’ in the form of an innate immune response in the infected cell. As a result,  
TRIM-mediated innate immune response could possibly establish an antiviral state in neighboring 
uninfected cells, which would serve to reduce the spread of certain retroviruses. It is possible that these 
two processes mediated by TRIM5α are coupled; however, it appears that human TRIM5-mediated 
innate immune response to HIV-1 capsid cannot efficiently control HIV-1 infection in humans given 
the existing AIDS pandemic. It might be possible that human TRIM5α plays a role in LPS-triggered 
immune activation through Toll-like  receptor  4-mediated  signaling,  which  has  been  linked  to  the 
progression of chronic HIV-1 infection [20].  Perhaps  HIV-1  has  evolved  other  yet  unknown 
mechanisms to escape TRIM5-mediated innate immune response in humans. For example, recent Viruses 2011, 3                         
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studies indicate that post-entry HIV-1 infection in human monocyte-derived dendritic cells and 
macrophages is blocked by a host protein named SAMHD1 [21,22]. This myeloid-cell-specific HIV-1 
restriction may allow HIV-1 to avoid antiviral innate immune responses derived from dendritic cells, a 
group of important antigen-presenting cells that bridge the innate and adaptive immunity [23]. Further 
investigation into the function and the mechanism of human TRIM5α as an innate immune sensor for 
retrovirus capsid might shed light to developing more effective interventions against HIV-1 infection. 
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